Ocugen (OCGN -3.53%), a biotechnology company developing gene therapies and regenerative medicine solutions for eye diseases, released its results for the second quarter of fiscal 2025 on August 1, 2025. GAAP revenue was $1.373 million, well above the$0.47 million analyst estimate (GAAP), as it secured new licensing agreements and continued R&D collaborations. The net loss per share (GAAP) narrowed to $(0.05), compared to consensus expectations of$(0.06) (GAAP) and last year's GAAP net loss per share was ...